How do you know that TA? Is that from discussions with the company or something you picked up in a presentation, cause it is not something I picked up in a presso.
If they do announce before the FDA interaction, I think it is a mistake.
You build confidence and trust with the market re 2591 by confirming that you have nailed the FDA meeting, have agreed on the endpoints and are proceeding with the trial and development of the drug.
Once that credibility is established for 2591 (the credibility that comes with venturing on an approved P3 trial in an unventured space), you then release the new indications to the market to add hope and excitement to the foundations of surety and trust.
I think if you release the new indications prior to the P3 FDA meeting, you are inciting hope and excitement in the potential of the drug but that is not what we need. I think anyone who spends 15 mins looking at the P2 trials, the MOA and the range of symptoms that improve already has hope and excitement. They don't have surety that the FDA sees a clear, approved path towards commercialisation.
Just my opinion only.
NEU Price at posting:
$11.65 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)